SG10201601660YA - Method of conferring a protective immune response to norovirus - Google Patents

Method of conferring a protective immune response to norovirus

Info

Publication number
SG10201601660YA
SG10201601660YA SG10201601660YA SG10201601660YA SG10201601660YA SG 10201601660Y A SG10201601660Y A SG 10201601660YA SG 10201601660Y A SG10201601660Y A SG 10201601660YA SG 10201601660Y A SG10201601660Y A SG 10201601660YA SG 10201601660Y A SG10201601660Y A SG 10201601660YA
Authority
SG
Singapore
Prior art keywords
norovirus
conferring
immune response
protective immune
protective
Prior art date
Application number
SG10201601660YA
Inventor
Charles Richardson
Thomas S Vedvick
Thomas R Foubert
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40468754&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201601660Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of SG10201601660YA publication Critical patent/SG10201601660YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SG10201601660YA 2007-09-18 2008-09-18 Method of conferring a protective immune response to norovirus SG10201601660YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97338907P 2007-09-18 2007-09-18
US98682607P 2007-11-09 2007-11-09

Publications (1)

Publication Number Publication Date
SG10201601660YA true SG10201601660YA (en) 2016-04-28

Family

ID=40468754

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201601660YA SG10201601660YA (en) 2007-09-18 2008-09-18 Method of conferring a protective immune response to norovirus
SG2012066726A SG184733A1 (en) 2007-09-18 2008-09-18 Method of conferring a protective immune response to norovirus

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012066726A SG184733A1 (en) 2007-09-18 2008-09-18 Method of conferring a protective immune response to norovirus

Country Status (10)

Country Link
US (4) US10130696B2 (en)
EP (1) EP2190471A4 (en)
JP (4) JP2010539192A (en)
KR (2) KR20150129042A (en)
CN (2) CN104740624B (en)
AU (1) AU2008302276B2 (en)
CA (1) CA2698397C (en)
HK (1) HK1211473A1 (en)
SG (2) SG10201601660YA (en)
WO (1) WO2009039229A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7955603B2 (en) 2006-09-29 2011-06-07 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations
SG179488A1 (en) 2007-03-14 2012-04-27 Ligocyte Pharmaceuticals Inc Virus like particle purification
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CN104740624B (en) 2007-09-18 2018-04-24 武田疫苗股份有限公司 Assign the vaccine of the protective immune response for norovirus
WO2010017542A1 (en) 2008-08-08 2010-02-11 Ligocyte Pharmaceuticals, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
US20120121710A1 (en) 2009-03-27 2012-05-17 Arizona Board Of Regents For And On Behalf Of Arizona State University Mucosal Immunization
JP5804453B2 (en) * 2009-05-14 2015-11-04 国立大学法人 東京大学 Crystalline polyol fine particles and preparation method thereof
US9439958B2 (en) * 2009-12-23 2016-09-13 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
WO2012006293A1 (en) * 2010-07-06 2012-01-12 Novartis Ag Norovirus derived immunogenic compositions and methods
FI122520B (en) * 2010-10-15 2012-03-15 Vesna Blazevic Norovirus capsid and rotavirus VP6 protein for use as a combination vaccine
EP2683402B1 (en) 2011-03-11 2020-06-24 Turnstone Limited Partnership A method of vaccination comprising a histone deacetylase inhibitor
ES2656527T3 (en) * 2011-07-11 2018-02-27 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
JP2014530224A (en) * 2011-10-12 2014-11-17 アルファ−オー・ペプチドズ・アーゲーＡｌｐｈａ−Ｏ Ｐｅｐｔｉｄｅｓ Ａｇ Self-assembled peptide nanoparticles as a vaccine against norovirus infection
CN102559616B (en) * 2012-02-24 2014-01-01 河南科技大学 Norovirus RNA fragment-containing pseudoviral particle and preparation method thereof
EP3607973A1 (en) * 2012-06-21 2020-02-12 Northwestern University Peptide conjugated particles
JOP20130186B1 (en) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc Purification of virus like particles
JP2015017065A (en) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ Pharmaceutical composition comprising norovirus virus-like particles
US9017698B2 (en) * 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
JP2016533172A (en) 2013-10-03 2016-10-27 タケダ ワクチン，インコーポレイテッド Methods for detecting and removing rhabdoviruses from cell lines
WO2015093452A1 (en) 2013-12-16 2015-06-25 武田薬品工業株式会社 Microneedle
JP2017507968A (en) * 2014-03-12 2017-03-23 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Liposome composition for mucosal delivery
AU2016317661B2 (en) 2015-08-28 2023-05-18 Ology Bioservices, Inc. Norovirus vaccine
JP6977206B2 (en) * 2016-03-31 2021-12-08 富山県 Mucosal vaccine adjuvant that activates innate immunity
CN107184970A (en) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 Oral norovirus subunit vaccine and LT as the vaccine adjuvant purposes
JP2021514391A (en) * 2018-02-15 2021-06-10 アイコン ジェネティクス ゲーエムベーハー Immunogenic compositions and vaccines to generate an immune response against norovirus
US20210308249A1 (en) * 2018-08-20 2021-10-07 Takeda Vaccines, Inc. Vlp formulations
JP2024519800A (en) 2021-05-21 2024-05-21 タケダ ワクチン，インコーポレイテッド Solid composition, freeze-drying method and glass vial

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
AU1893592A (en) 1991-03-25 1992-10-21 Board Of Trustees Of The Leland Stanford Junior University Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas
JPH07509122A (en) 1992-04-08 1995-10-12 ザ　ガバメント　オブ　ザ　ユナイテッド　ステイツ　オブ　アメリカ，アズ　レプリゼンテッド　バイ　ザ　セクレター，デパートメント　オブ　ヘルス　アンド　ヒューマン　サービシーズ Wild-type measles virus glycoprotein: vaccines and methods for their detection
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
HUT76354A (en) 1994-05-16 1997-08-28 Merck & Co Inc Papillomavirus vaccines
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
JP4598201B2 (en) 1997-04-08 2010-12-15 メルク・シャープ・エンド・ドーム・コーポレイション Stabilized human papillomavirus preparation
WO1998050071A1 (en) 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
ATE324436T1 (en) 1998-08-14 2006-05-15 Merck & Co Inc METHOD FOR CLEANING HUMAN PARTICLES SIMILAR TO THE PAPILLOMA VIRUS.
WO2000035479A1 (en) 1998-12-17 2000-06-22 Merck & Co., Inc. Synthetic virus-like particles with heterologous epitopes
PT1150712E (en) 1999-02-05 2008-12-22 Merck & Co Inc Human papilloma virus vaccine formulations
WO2000079280A1 (en) 1999-06-22 2000-12-28 Japan As Represented By Director-General National Institute Of Infectious Diseases Srsv detection kit
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
WO2003068804A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Novel insect cell line
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
AU2003237528A1 (en) 2002-06-07 2003-12-22 Kentucky Bioprocessing, Llc Flexible vaccine assembly and vaccine delivery platform
DE60335186D1 (en) 2002-06-20 2011-01-13 Cytos Biotechnology Ag PACKAGED VIRUS PARTICLES IN COMBINATION WITH CPG FOR USE AS ADJUVANTIES WITH ALLERGENS. MANUFACTURING METHOD AND USE
US20050106178A1 (en) 2003-01-30 2005-05-19 Chiron Corporation Adjuvanted influenza vaccine
WO2004073652A2 (en) 2003-02-20 2004-09-02 Becton Dickinson And Company Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
WO2005030806A2 (en) 2003-09-24 2005-04-07 Montana State University Norovirus monoclonal antibodies and peptides
WO2005037223A2 (en) 2003-10-15 2005-04-28 Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (en) 2003-12-19 2006-03-24 Aventis Pasteur IMMUNOSTIMULATING COMPOSITION
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (en) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech VACCINE COMPOSITION AGAINST THE VIRUS OF HEPATITIS C
EP1809325B1 (en) 2004-10-20 2013-11-20 Sanofi Pasteur Biologics, LLC Vaccines against japanese encephalitis virus
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
AU2006203985A1 (en) 2005-01-05 2006-07-13 Philadelphia Health And Education Corporation Delivery vehicles, bioactive substances and viral vaccines
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
CA2598488A1 (en) 2005-02-18 2006-08-31 Novartis Vaccines And Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
CN103203016A (en) 2005-03-18 2013-07-17 赛托斯生物技术公司 Cat Allergen Fusion Proteins And Uses Thereof
JP2009501001A (en) 2005-06-01 2009-01-15 ダウ グローバル テクノロジーズ インコーポレイティド Production of multivalent virus-like particles
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
JP2007145775A (en) 2005-11-29 2007-06-14 Falco Life Science:Kk Method for detecting norovirus gi in high sensitivity
US7955603B2 (en) 2006-09-29 2011-06-07 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations
NZ577405A (en) 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
SG179488A1 (en) 2007-03-14 2012-04-27 Ligocyte Pharmaceuticals Inc Virus like particle purification
CN104740624B (en) 2007-09-18 2018-04-24 武田疫苗股份有限公司 Assign the vaccine of the protective immune response for norovirus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
WO2010017542A1 (en) 2008-08-08 2010-02-11 Ligocyte Pharmaceuticals, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
EP2381959A1 (en) 2009-01-22 2011-11-02 Pharmathene Inc. Stable vaccine compositions and methods of use
EP2942062A1 (en) 2009-02-10 2015-11-11 Novartis AG Influenza vaccine regimens for pandemic-associated strains
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
JP2013517773A (en) 2010-01-21 2013-05-20 リゴサイト ファーマスーティカルズ，インコーポレイテッド Targeted heterologous antigen presentation on calicivirus virus-like particles
EP3388081A1 (en) 2010-05-26 2018-10-17 Selecta Biosciences, Inc. Multivalent synthetic nanocarrier vaccines
ES2656527T3 (en) 2011-07-11 2018-02-27 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
JOP20130186B1 (en) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc Purification of virus like particles
FI3827838T3 (en) 2015-12-16 2023-06-19 Walter & Eliza Hall Inst Medical Res Inhibition of cytokine-induced sh2 protein in nk cells
GB2605540B (en) 2016-10-18 2022-12-21 Univ Minnesota Tumor infiltrating lymphocytes and methods of therapy
SG11202010763VA (en) 2018-05-03 2020-11-27 Univ Texas Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
US20210308249A1 (en) 2018-08-20 2021-10-07 Takeda Vaccines, Inc. Vlp formulations
AR117462A1 (en) 2018-12-20 2021-08-04 Takeda Vaccines Inc VACCINE AGAINST NOROVIRUS, FORMULATIONS AND METHODS
SG11202108644UA (en) 2019-02-15 2021-09-29 Editas Medicine Inc Modified natural killer (nk) cells for immunotherapy

Also Published As

Publication number Publication date
CN101918028A (en) 2010-12-15
KR20100083150A (en) 2010-07-21
HK1211473A1 (en) 2016-05-27
CA2698397C (en) 2018-03-27
US20220143169A1 (en) 2022-05-12
SG184733A1 (en) 2012-10-30
KR20150129042A (en) 2015-11-18
CN104740624B (en) 2018-04-24
JP2019163328A (en) 2019-09-26
JP6296885B2 (en) 2018-03-20
US10688174B2 (en) 2020-06-23
US11040097B2 (en) 2021-06-22
CN101918028B (en) 2015-01-07
US20110182975A1 (en) 2011-07-28
JP2016196502A (en) 2016-11-24
US20200345827A1 (en) 2020-11-05
US11826415B2 (en) 2023-11-28
CA2698397A1 (en) 2009-03-26
AU2008302276A1 (en) 2009-03-26
US20190381164A1 (en) 2019-12-19
AU2008302276B2 (en) 2013-10-10
EP2190471A2 (en) 2010-06-02
WO2009039229A3 (en) 2009-09-03
JP6615063B2 (en) 2019-12-04
WO2009039229A2 (en) 2009-03-26
JP2010539192A (en) 2010-12-16
EP2190471A4 (en) 2012-05-09
JP2014141528A (en) 2014-08-07
US10130696B2 (en) 2018-11-20
CN104740624A (en) 2015-07-01

Similar Documents

Publication Publication Date Title
SG10201601660YA (en) Method of conferring a protective immune response to norovirus
GB2517100B (en) Method of optical sensing
EP2447143A4 (en) Motorcycle
PL2516765T3 (en) Seismic clip
EP2211903A4 (en) Antibodes to cll-1
AU332003S (en) Motorcycle
GB201006297D0 (en) Metadata browser
PL2260153T3 (en) Fire protection of a structural element
EP2447139A4 (en) Motorcycle
EP2461670A4 (en) Protective petwear
ZA201207027B (en) Motorcycle rear portion structure
SI2208664T1 (en) Handlebar protection
PL2338679T3 (en) Protective covering
HK1145057A2 (en) A protective cover for a pair of spectacles
GB0822028D0 (en) Protective suit
EP2225176A4 (en) Methods of recovering silane
TWI509413B (en) Os protecting method
EP2395152A4 (en) Motorcyclist protection system
GB0903451D0 (en) Protective jacket
AU329732S (en) Motorcycle
GB201017590D0 (en) Motorcycle front suspension
GB0919013D0 (en) Easy rider
TWI366532B (en) Motorcycle
GB2463553B (en) Clock for motorcycle
TWM372813U (en) Structure of bike hangar